Cargando…

M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma

BACKGROUND AND OBJECTIVES: The relationship between the tumor microenvironment and the network of key signaling pathways in cancer plays a key role in the occurrence and development of tumors. Tumor-associated macrophages (TAMs) are important inflammatory cells in the tumor microenvironment and play...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Long, Han, Pinsheng, Cui, Tao, Miao, Yu, Zhao, Tianyu, Cui, Zilin, Chen, Yijia, Chi, Hao, Zhang, Jieying, Zhang, Yamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556255/ https://www.ncbi.nlm.nih.gov/pubmed/37809069 http://dx.doi.org/10.3389/fimmu.2023.1251648

Ejemplares similares

Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
por: Zhang, Wei, et al.
Publicado: (2023)

CD86(+)/CD206(+) tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma
por: Sun, Dalong, et al.
Publicado: (2020)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)

A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma
por: Gong, Yinhua, et al.
Publicado: (2023)

Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report
por: Zhang, Jun-Wei, et al.
Publicado: (2023)

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
por: Ding, Yuan, et al.
Publicado: (2021)

Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest
por: Yan, Xia, et al.
Publicado: (2023)

Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma
por: Chai, Xiaoqiang, et al.
Publicado: (2022)

Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma
por: Wei, Zhanqi, et al.
Publicado: (2023)

Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3
por: Zhou, Zhengjun, et al.
Publicado: (2021)

Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
por: Zhang, Xi, et al.
Publicado: (2022)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
por: Ding, Xiaoyan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis
por: Sun, Bao-Ye, et al.
Publicado: (2022)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma
por: Xu, Linping, et al.
Publicado: (2022)

AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway
por: Deng, Liming, et al.
Publicado: (2023)

Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
por: Zhang, Zhongyan, et al.
Publicado: (2023)

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
por: Wang, Zhihong, et al.
Publicado: (2021)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

Tumor-associated macrophages in tumor progression and the role of traditional Chinese medicine in regulating TAMs to enhance antitumor effects
por: Zhang, Jiatong, et al.
Publicado: (2022)

A2M is a potential core gene in intrahepatic cholangiocarcinoma
por: Zhang, Guanran, et al.
Publicado: (2022)

High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma
por: Ma, Bingqi, et al.
Publicado: (2021)

Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness
por: Yuan, Hui, et al.
Publicado: (2020)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages
por: Li, Xi, et al.
Publicado: (2020)

Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review
por: Chen, Wei-xun, et al.
Publicado: (2019)

Overexpression of FoxM1 predicts poor prognosis of intrahepatic cholangiocarcinoma
por: Liu, Lingyun, et al.
Publicado: (2018)

Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma
por: Zeng, Tian-mei, et al.
Publicado: (2022)

Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages
por: Müller, Elisabeth, et al.
Publicado: (2017)

Development and Validation of a Nomogram for Differentiating Combined Hepatocellular Cholangiocarcinoma From Intrahepatic Cholangiocarcinoma
por: Wang, Tao, et al.
Publicado: (2020)

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
por: Zhu, Chengpei, et al.
Publicado: (2023)

Two Varieties of Intrahepatic Cholangiocarcinoma
por: Nagorney, David M.
Publicado: (1994)

Intrahepatic Cholangiocarcinoma with Sarcomatous Changes
por: Inoue, Yoshiyuki, et al.
Publicado: (2012)

Serum Markers of Intrahepatic Cholangiocarcinoma
por: Malaguarnera, Giulia, et al.
Publicado: (2013)

Intrahepatic cholangiocarcinoma: current perspectives
por: Buettner, Stefan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rqlq00u0i7l6upj3r18oms3r64